PEGBIO CO-B (02565)'s core product Peidakang (pegmivalapenta injection) has been successfully included in the 2026 National Reimbursement Drug List.
PEGBIO CO-B (02565) announced that the Group's independently developed core innovative drug product pegmivalapenta injection (trade name: Peidakang, hereinafter referred to as "Peidakang") has been successfully included in the "2026 National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance" newly released by the National Healthcare Security Administration.
PEGBIO CO-B (02565) announced that the Group's core innovative drug product developed independently, pegmivalapenta injection (trade name: Peidakang, hereinafter referred to as "Peidakang"), has been successfully included in the "2026 National Drug Catalog for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance" newly released by the National Healthcare Security Administration.
The successful inclusion of Peidakang in the National Reimbursement Drug List marks an important breakthrough for the Group's first commercialized innovative drug product in terms of access to the national healthcare security system, and is also an important milestone for the Group in advancing from innovative R&D to large-scale commercialization.
Peidakang is a National Class 1 innovative drug independently developed by the Group. It is a once-weekly long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) that was approved for marketing by the National Medical Products Administration in November 2025 for glycemic control in adult patients with type 2 diabetes.
As the Group's first approved innovative drug product, Peidakang features differentiated clinical characteristics such as immediate treatment upon initiation and no need for dose titration. Results from its pivotal clinical studies show that Peidakang can achieve sustained and stable glycemic control, providing a new treatment option for Chinese adult patients with type 2 diabetes.
Related Articles

GALAXIS TECH (02729) plans to implement an H-share repurchase plan, with the total repurchase amount not exceeding HK$100 million.

GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.
GALAXIS TECH (02729) plans to implement an H-share repurchase plan, with the total repurchase amount not exceeding HK$100 million.

GENFLEET-B(02595): Pan-RAS inhibitor GFH276 combination therapy study in pancreatic cancer completes first patient dosing in China and overseas; Phase II stage will include three first-line combination treatment regimens

Palm Eco-Town Development (002431.SZ) initiates out-of-court restructuring matters.






